The therapeutic response to insulin lispro should be monitored by periodic blood glucose testing through the day with a glucometer or by obtaining serum glucose. Glycosylated hemoglobin should be obtained to measure long-term glycemic control on a quarterly to bi-annual basis depending on whether or not patients have stable glycemic control and are meeting their treatment goals.